grow
emerg
pandrugresist
acinetobact
baumannii
pdrab
strain
clinic
new
strategi
treatment
pdrab
infect
urgent
need
egg
yolk
immunoglobulin
igi
conveni
inexpens
antibodi
wide
appli
therapi
infecti
diseas
aim
studi
produc
igi
specif
pdrab
investig
antibacteri
effect
vitro
vivo
igi
specif
two
pdrab
strain
produc
immun
hen
formaldehyd
inactiv
pdrab
cell
isol
yolk
puriti
water
dilut
salt
precipit
ultrafiltr
igi
show
high
titer
subject
elisa
inhibit
growth
pdrab
dosedepend
manner
liquid
medium
scan
electron
microscopi
assay
show
structur
modif
aggreg
pdrab
treat
specif
igi
freshli
cultur
pdrab
cell
nasal
inhal
balbc
mice
induc
acut
pneumonia
infect
mice
intraperiton
inject
specif
igi
use
cefoperazonesulbactam
dexamethason
posit
control
igi
specif
pdrab
lower
mortal
mice
pdrabinduc
acut
pneumonia
decreas
level
serum
reduc
inflamm
lung
tissu
specif
igi
potenti
use
new
therapeut
approach
treatment
baumanniiinduc
infect
http
dx
acinetobact
baumannii
baumannii
one
common
nosocomi
acinetobact
belong
nonfer
gramneg
bacilli
baumannii
respons
mani
kind
nosocomi
infect
hospit
acquir
sepsi
pneumonia
especi
ventilatorassoci
pneumonia
vap
skin
softtissu
infect
wound
infect
urinari
tract
infect
secondari
mening
bloodstream
infect
past
year
nosocomi
outbreak
due
baumannii
report
increasingli
caus
great
threat
patient
icu
increas
mortal
hospit
stay
medicin
cost
wide
use
broadspectrum
antibacteri
strain
baumannii
resist
multipl
antimicrobi
agent
infect
caus
baumannii
difficult
cure
multipl
intrins
acquir
mechan
make
bacteria
frequent
multidrugresist
mdr
antimicrobi
serious
pandrugresist
baumannii
pdrab
defin
resist
nearli
routin
test
antimicrobi
increasingli
report
littl
drug
applic
face
pdrab
infect
antibacteri
resist
ubiquit
relentless
clinic
problem
compound
lack
new
therapeut
agent
predica
new
antibacteri
develop
pharmaceut
industri
promot
innov
antimicrobi
therapi
biomed
field
use
antibodi
egg
yolk
immunoglobulin
igi
antibodi
transfer
serum
egg
yolk
poultri
order
protect
develop
embryo
potenti
pathogen
use
antigenspecif
immun
respons
mass
specif
igi
obtain
egg
yolk
lay
hen
recent
igi
attract
consider
interest
therapeut
diagnost
agent
specif
igi
wide
appli
treatment
infecti
diseas
caus
variou
kind
bacteria
includ
escherichia
coli
helicobact
pylori
salmonella
staphylococcu
aureu
streptococcu
mutant
yersinia
ruckeri
infect
caus
viru
rotaviru
coronaviru
enteroviru
could
also
interf
specif
igi
even
igi
specif
baumannii
report
differ
tradit
antibacteri
specif
igi
environmentallyfriendli
elicit
undesir
side
effect
drug
resist
toxic
residu
addit
igi
possess
larg
number
advantag
mammalian
igg
costeffect
conveni
high
yield
studi
prepar
two
igi
respect
two
pdrab
strain
differ
sourc
estim
antibacteri
activ
vitro
vivo
provid
refer
use
igi
treatment
pdrab
infect
baumannii
atcc
name
abb
studi
obtain
american
type
cultur
collect
atcc
clinic
isol
strain
baumannii
name
abc
isol
sputum
patient
dalian
friendship
hospit
two
strain
identifi
pdrab
drug
sensit
test
previou
studi
hen
use
immun
hylin
lay
hen
hous
commerci
poultri
facil
dalian
china
male
balbc
mice
weigh
approxim
g
obtain
anim
care
center
dalian
medic
univers
dalian
china
experi
mice
day
adapt
experiment
environ
experi
perform
accord
experiment
anim
manag
law
china
approv
anim
ethic
committe
dalian
medic
univers
pdrab
strain
abb
abc
respect
use
antigen
igi
product
abb
abc
cultur
tryptic
soy
broth
tsb
media
h
collect
pb
concentr
cfu
ml
inactiv
wv
formaldehyd
h
inactiv
antigen
suspens
emulsifi
equal
volum
complet
incomplet
freund
adjuv
first
subsequ
booster
immun
respect
hen
immun
accord
report
method
fifteen
hylin
lay
hen
divid
three
group
immun
two
vaccin
pb
respect
hen
inject
intramuscularli
three
site
total
volum
ml
first
inject
ml
two
booster
immun
interv
egg
collect
daili
immun
hen
first
inject
store
use
egg
yolk
dilut
six
volum
distil
water
ph
adjust
suspens
store
overnight
clarifi
centrifug
g
water
solubl
fraction
wsf
collect
success
precipit
satur
ammonium
sulfat
wv
sodium
sulfat
precipit
resuspend
distil
water
ultrafilt
vivaflow
tangenti
flow
ultrafilt
vivasci
hannov
germani
cutoff
membran
lyophil
obtain
igi
powder
puriti
igi
obtain
differ
phase
isol
assess
mean
sodium
dodecyl
sulfat
polyacryl
amid
gel
electrophoresi
sdspage
standard
igi
puriti
promega
madison
wi
use
refer
sdspage
carri
nonreduc
condit
gel
trisglycin
system
stain
coomassi
brilliant
blue
accord
manufactur
recommend
titer
igi
specif
abb
bigi
abc
cigi
determin
enzymelink
immunosorb
assay
elisa
conduct
wsf
fraction
microtit
plate
coat
abb
abc
concentr
cfuml
wsf
fraction
firstli
dilut
pb
serial
twofold
dilut
wsf
fraction
dilut
egg
nonimmun
hen
serum
dilut
immun
hen
pb
use
neg
posit
blank
control
respect
horseradish
peroxidas
coupl
rabbit
antichicken
igg
sigmaaldrich
st
loui
usa
dilut
use
secondari
antibodi
reaction
stop
h
mlwell
reagent
ad
volum
ml
well
optic
densiti
od
nm
read
micropl
reader
use
nm
refer
wavelength
od
sampl
od
neg
correspond
dilut
multipl
sampl
determin
igi
titer
lyophil
bigi
cigi
powder
titer
dissolv
tsb
liquid
medium
concentr
mgml
nonspecif
igi
powder
dissolv
medium
concentr
mgml
solut
steril
freshli
cultur
abb
abc
cell
respect
ad
final
concentr
cfuml
tsb
liquid
medium
use
blank
control
medium
contain
pdrab
use
neg
control
cefoperazonesulbactam
pfizer
america
concentr
mgml
use
posit
control
mixtur
bacteria
igi
incub
shake
rpm
od
nm
valu
suspens
measur
micropl
reader
thermo
fisher
scientif
waltham
usa
h
interv
blank
control
ie
e
coli
growth
curv
reach
stationari
phase
lyophil
bigi
cigi
powder
titer
dissolv
pb
contain
bsa
concentr
mgml
nonspecif
igi
concentr
use
control
solut
steril
abb
abc
ad
final
concentr
cfuml
suspens
incub
h
centrifug
rpm
min
sediment
wash
pb
twice
prepar
specimen
sem
assay
observ
use
electron
microscop
fei
america
seventytwo
mice
divid
six
group
one
group
use
blank
control
other
model
acut
pneumonia
clinic
isol
strain
abc
use
induc
acut
pneumonia
mice
freshli
cultur
abc
cell
cfuml
nasal
inhal
balbc
mice
dose
acut
pneumonia
mice
determin
statu
observ
histopatholog
examin
lung
tissu
powder
specif
igi
titer
dissolv
nacl
mgml
steril
filter
mgml
cefoperazonesulbactam
mgml
dexamethason
shuangh
pharmaci
compani
china
use
posit
control
nacl
use
neg
control
mice
receiv
intraperiton
inject
agent
dose
mgkg
except
dexamethason
mgkg
h
pdrab
challeng
receiv
one
inject
doubl
dose
h
infect
statu
mice
observ
mortal
within
h
record
eighteen
balbc
mice
divid
six
group
one
group
use
blank
control
other
nasal
infect
freshli
cultur
abc
cell
cfuml
dose
infect
mice
treat
igi
posit
agent
describ
blood
collect
mice
retroorbit
punctur
h
infect
serum
sampl
prepar
store
level
tumor
necrosi
serum
detect
commerci
elisa
kit
jingmei
biotech
beij
china
six
hour
blood
collect
infect
mice
kill
histopatholog
detect
lung
tissu
mice
fix
neutral
buffer
formalin
embed
paraffin
section
stain
hematoxylin
eosin
h
e
stain
tissu
section
examin
microscop
scientist
know
treatment
experiment
anim
assign
statist
analysi
conduct
use
spss
window
spss
inc
chicago
il
usa
data
repres
mean
standard
deviat
sd
level
signific
evalu
use
lsd
test
differ
consid
signific
level
p
igi
isol
yolk
immun
hen
water
dilut
purifi
salt
precipit
ultrafiltr
igi
molecular
weight
kda
visual
fig
puriti
igi
increas
significantli
sodium
sulfat
precipit
ultrafiltr
document
sdspage
electrophoret
pattern
ultrafiltr
fraction
line
standard
igi
puriti
elisa
reveal
abil
two
specif
igi
bind
baumannii
show
pattern
immun
respons
hen
day
titer
bigi
produc
abbimmun
hen
increas
day
initi
immun
reach
day
highest
titer
reach
day
maintain
day
fig
titer
cigi
produc
abcimmun
hen
increas
day
initi
immun
reach
day
highest
titer
reach
day
maintain
day
fig
contrari
titer
igi
produc
hen
immun
pb
extrem
low
two
igi
could
inhibit
growth
two
antigen
strain
liquid
medium
dosedepend
manner
concentr
rang
mgml
mgml
fig
nonspecif
igi
show
signific
growth
inhibit
bacteria
howev
inhibit
effect
bigi
cigi
clinic
isol
strain
abc
lower
abb
whole
growth
pdrab
could
inhibit
specif
igi
differ
extent
could
hardli
inhibit
nonspecif
igi
sem
assay
show
morpholog
baumannii
chang
greatli
bacteria
treat
specif
igi
fig
crenat
structur
modif
aggreg
could
observ
two
pdrab
strain
treat
specif
igi
contrast
bacteria
grown
nonspecif
igi
alon
view
dispers
smooth
integr
cluster
piloerect
hypothermia
tachypnea
could
observ
abc
infect
mice
histopatholog
detect
show
inflammatori
cell
infiltr
lung
tissu
fig
mice
acut
pneumonia
treat
specif
igi
antibacteri
antiinflammatori
agent
respect
show
tabl
death
happen
uninfect
mice
within
h
death
mice
group
occur
within
h
infect
mortal
mice
neg
control
group
dexamethasonetr
group
cefoperazonesulbactamtr
group
mortal
decreas
mice
protect
two
specif
igi
individu
abil
two
specif
igi
prevent
mice
pdrabinduc
death
stronger
cefoperazonesulbactam
dexamethason
level
proinflammatori
cytokin
serum
mice
determin
elisa
level
infect
mice
increas
rapidli
pdrab
challeng
reach
highest
valu
h
decreas
tabl
valu
specif
igystr
mice
significantli
lower
posit
control
neg
control
mice
p
h
treatment
specif
igystr
mice
recoverd
normal
level
amount
cefoperazonesulbactam
dexamethasontr
mice
still
high
level
much
lower
neg
control
mice
p
level
chang
similar
trend
tabl
result
indic
specif
igi
could
p
decreas
level
proinflammatori
cytokin
pdrab
infect
mice
protect
effect
specif
igi
pdrabinfect
mice
assess
histopatholog
examin
lung
tissu
section
fig
h
e
stain
section
lung
neg
control
mice
h
show
seriou
infiltr
neutrophil
fill
alveolar
compar
normal
control
lung
tissu
fig
b
patholog
featur
consist
acut
pneumonia
signific
attenu
patholog
featur
lung
tissu
mice
treat
cefoperazonesulbactam
dexamethason
fig
mild
edema
alveolar
observ
section
lung
specif
igystr
mice
infiltr
inflammatori
cell
view
fig
f
result
demonstr
efficaci
specif
igi
pdrab
infect
baumannii
kind
ubiquit
nonfer
gramneg
bacillu
commonli
associ
aquat
environ
owe
high
abil
colon
warm
humid
environ
natur
genet
transform
baumannii
current
exceed
bacteria
commonli
pathogen
clinic
laboratori
chittawatanarat
et
al
found
gram
neg
bacteria
major
pathogen
vap
among
baumannii
rank
first
aggrav
antibacteri
abus
recent
year
baumannii
resist
multipl
antimicrobi
agent
includ
antibacteri
aminoglycosid
tetracyclin
quinolon
exist
antibacteri
noth
infect
caus
pdrab
strain
previou
studi
obtain
seven
strain
baumannii
respiratori
depart
icu
hospit
determin
pdrab
chemosensit
test
twelv
antimicrobi
agent
includ
minocyclin
amikacin
ceftriaxon
ceftazidim
cefepim
cefoperazon
piperacillin
ticarcillin
meropenem
trimethoprimsulfamethoxazol
levofloxacin
ciprofloxacin
test
strain
abc
use
studi
one
pdrab
baumannii
strain
abb
use
also
determin
pdrab
test
gener
carbapenem
antibacteri
first
choic
pdrab
infect
first
nosocomi
carbapenemresist
baumannii
crab
strain
report
crab
strain
shown
increas
document
report
baumannii
mdrab
baumannii
resist
imipenem
sever
mechan
respons
resist
crab
among
product
oxacillinas
oxa
enzym
import
one
document
pdrab
strain
use
studi
resist
meropenem
new
carbapenem
antibacteri
posit
enzym
two
mdrab
strain
suitabl
estim
activ
new
antibacteri
agent
baumannii
studi
use
two
pdrab
strain
obtain
differ
sourc
antigen
produc
specif
igi
result
bacteriostat
test
demonstr
two
specif
igi
crossreact
two
pdrab
strain
besid
antibacteri
test
strain
mdrab
mention
previous
two
specif
igi
also
show
antibacteri
activ
supplementari
fig
onlin
version
doi
http
suggest
igi
one
pdrab
strain
might
applic
baumannii
strain
gramneg
bacteria
baumannii
caus
diseas
fig
lung
histopatholog
baumanniiinfect
mice
receiv
differ
treatment
blank
group
lung
tissu
normal
mice
b
neg
group
lung
tissu
infect
mice
treat
c
cefoperazonesulbactam
group
lung
tissu
infect
mice
treat
cefoperazonesulbactam
dexamethason
group
lung
tissu
infect
mice
treat
dexamethason
e
bigi
group
lung
tissu
infect
mice
treat
bigi
f
cigi
group
lung
tissu
infect
mice
treat
bigi
mortal
abc
infect
mice
differ
treatment
vitro
studi
indic
specif
igi
inhibit
growth
pdrab
dosedepend
manner
antibacteri
activ
two
specif
igi
compar
cefoperazonesulbactam
bigi
cigi
mgml
could
significantli
inhibit
growth
pdrab
within
h
whole
inhibitori
effect
igi
abc
weaker
abb
isol
clinic
sampl
abc
resist
antibacteri
wider
stronger
degre
therefor
use
abc
modelbuild
strain
murin
acut
pneumonia
studi
sem
assay
indic
specif
igi
enhanc
agglutin
mdrab
report
igi
could
enhanc
agglutin
bacteria
caus
reduct
cfu
rather
actual
direct
effect
individu
bacteria
sem
assay
also
show
cell
crenat
structur
modif
surfac
specif
igystr
bacteria
result
combin
igi
bacteria
might
reduc
attach
bacteria
mucosa
similar
function
specif
igi
ever
report
helicobact
pylori
attach
gastric
cancer
cell
salmonella
attach
intestin
cell
addit
agglutin
adherenceblockad
phagocytosi
opson
anoth
import
mechan
igi
mediat
antibacteri
activ
infect
quantiti
macrophag
local
infect
tissu
increas
recruit
circul
monocyt
andor
situ
prolifer
activ
macrophag
proinflammatori
phenotyp
produc
variou
proinflammatori
mediat
play
central
role
inflammatori
process
igi
bind
may
alter
electron
cloud
andor
electr
field
bacteri
surfac
consequ
increas
vulner
bacteria
cell
phagocytosi
previou
studi
demonstr
specif
igi
increas
phagocytosi
aureu
milk
macrophag
nie
et
al
reveal
igi
improv
phagocytosi
aureu
neutrophil
studi
though
increas
proinflammatori
cytokin
observ
model
mice
level
specif
igystr
mice
much
lower
recov
normal
rapidli
group
infer
igi
might
improv
phagocytosi
macrophag
pdrab
result
quantiti
macrophag
recruit
activ
infect
tissu
decreas
proinflammatori
cytokin
produc
macrophag
reduc
previous
prove
protect
effect
specif
igi
substitut
antibacteri
rat
prevotella
intermediamedi
gingiv
mice
lipopolysaccharideinduc
endotoxemia
studi
mice
model
abinduc
acut
pneumonia
build
nasal
inhal
pdrab
use
estim
efficaci
specif
igi
baumannii
pneumonia
common
diseas
respiratori
system
vap
caus
multidrug
resist
gramneg
pathogen
especi
pdrab
threat
patient
icu
critic
novel
antibacteri
latestag
clinic
develop
clinician
may
soon
left
littl
choic
treatment
pdrab
infect
present
studi
indic
igi
pdrab
could
prevent
pneumon
mice
death
attenu
inflamm
infect
lung
cefoperazonesulbactam
dexamethason
use
posit
control
compar
igi
studi
cefoperazonesulbactam
compound
prepar
cephalosporin
inhibitor
show
stronger
antibacteri
activ
specif
igi
vitro
death
prevent
antiinflammatori
effect
vivo
much
lower
specif
igi
dexamethason
antiinflammatori
glucocorticoid
show
death
prevent
effect
littl
antiinflammatori
effect
mice
acut
pneumonia
downregul
effect
dexamethason
compar
specif
igi
base
specif
igi
effect
cefoperazonesulbactam
dexamethason
pdrab
vitro
vivo
consid
advantag
togeth
specif
igi
may
promis
substitut
current
antibacteri
conclus
specif
igi
produc
immun
lay
hen
pdrab
abl
inhibit
growth
baumannii
dosedepend
manner
protect
mice
acut
pneumonia
induc
baumannii
specif
igi
potenti
use
new
therapeut
approach
treatment
pdrab
infect
data
present
mean
sd
n
p
compar
blank
control
time
p
compar
neg
control
time
